Avidity Biosciences Inc.

Address: 3020 Callan Road

Sponsor Overview

assignment

Specializations

Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Inc. funds clinical research in facioscapulohumeral muscular dystrophy, with studies centered on muscle function, mobility, and disease-related weakness in affected adults.

Functional mobility
Muscle strength
Neuromuscular disease

Its clinical activity in this area reflects a focus on therapies for inherited muscle disorders that affect movement and daily physical performance.

Myotonic Dystrophy Type 1

The sponsor also supports research in myotonic dystrophy type 1, with attention to hand function, long-term tolerability, and the broader burden of this multisystem neuromuscular disorder.

Hand function
Long-term safety
Inherited muscle disease

This area of interest includes clinical evaluation of treatments intended for chronic motor impairment associated with DM1.

Muscle Disease Therapeutics

Avidity Biosciences Inc. is active in therapeutic development for rare muscle diseases, particularly conditions that involve progressive weakness and reduced limb or hand performance.

Rare disease treatment
Progressive muscle weakness
Motor impairment

The funded studies emphasize clinical endpoints tied to physical function in inherited muscular dystrophy populations.

Neuromuscular Clinical Development

The sponsor’s trial portfolio is concentrated in neuromuscular medicine, covering patient groups with genetic muscle disorders across multiple active study sites and countries.

Genetic neuromuscular disorders
Adult neurology
Multinational clinical research

Its research landscape is defined by ongoing clinical evaluation in disorders where muscle performance and daily function are central therapeutic concerns.

Sponsored Trials

Trial Name	Country	Status
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)	Italy The Netherlands	Not Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)	Denmark France Germany Italy Spain The Netherlands	Recruiting
Evaluation of the Efficacy and Safety of Intravenous AOC 1001 in Myotonic Dystrophy Type 1: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study	Denmark France Germany Ireland Italy Spain The Netherlands	Not Recruiting
Phase 3 Study of Delpacibart Zotadirsen in Duchenne Muscular Dystrophy with Mutations Amenable to Exon 44 Skipping	Belgium France Germany Italy Poland Spain The Netherlands	Recruiting
Phase 3 Study on Long-Term Safety and Efficacy of Intravenous AOC 1001 in Myotonic Dystrophy Type 1	Denmark France Germany Italy Spain The Netherlands	Recruiting